Human factors validation study of a disposable autoinjector (Bmab 1200 autoinjector) for subcutaneous delivery of Ustekinumab.
Ustekinumab is approved for treating moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. The Bmab 1200 autoinjector is a simple, two-step device for subcutaneous ustekinumab biosimilar delivery. This was an in vitro, nonclinical, simulated-use human fac…
Differential transcriptional and epigenetic signatures in CD4+ T cells separate enthesitis related and psoriatic juvenile idiopathic arthritis - a pilot study.
Juvenile idiopathic arthritis (JIA) is the most common musculoskeletal rheumatic disease affecting children. Following the currently used International League of Associations for Rheumatology (ILAR) classification, JIA encompasses seven clinically defined subtypes all of which share chronic inflamma…
Association between patient characteristics, demographics, and social determinants of health with treatment-refractory and complex-to-manage psoriatic arthritis.
Psoriatic arthritis (PsA) is a heterogeneous disease that presents challenges in both diagnosis and treatment. To address the disease burden, the Group of Research and Association of Psoriasis and Psoriatic Arthritis conducted surveys with patients to gain insights into patient experiences regarding…
A Case Series of Raynaud's Phenomenon in the Setting of Immune Checkpoint Inhibitors.
Although immune checkpoint inhibitors (ICIs) have improved oncological outcomes, they can cause a myriad of inflammatory conditions known as immune-related adverse events (irAEs). Raynaud's phenomenon (RP) is a rare rheumatologic irAE that may arise de novo or present as an exacerbation of preexisti…
Capsulectomy at Explant: Rethinking Spinal Cord Stimulator Infected Generator Pocket Management in the Immunocompromised-A Case Series.
Surgical site infections (SSI) associated with spinal cord stimulation (SCS) implants pose risks of morbidity, mortality, and increased healthcare costs. Immunocompromised patients are especially vulnerable due to impaired immune responses, delaying diagnosis and increasing complications. Current gu…
Effectiveness of interleukin (IL)-23 and IL-12/23 inhibitors and factors associated with response in psoriatic arthritis with axial involvement: the APxis-IL12-23 study.
To assess the real-world effectiveness of two interleukin (IL)-23 inhibitors [guselkumab (GUS), risankizumab (RIS)] and an IL-12/23 inhibitor [ustekinumab (UST)] in patients with purely axial psoriatic arthritis (PsA) or mixed PsA (both axial and peripheral involvement), and identify response predic…
Clinic-Based Proportion of Psoriatic Arthritis and HLA-B27 Distribution in Korean Psoriasis Patients: A Retrospective Study.
Psoriatic arthritis (PsA) develops in up to one-third of patients with psoriasis over the disease course, and the genetic factors are thought to modulate susceptibility. Although HLA-B27 has long been implicated in PsA, its clinical utility for identifying PsA in East Asian populations remains uncer…
Exploring potential association between bisphenol A exposure and spondyloarthritis: Integrative evidence from molecular analyses and NHANES.
Spondyloarthritis (SpA), including ankylosing spondylitis (AS) and psoriatic arthritis (PsA), involves complex interactions between genetic susceptibility and environmental factors. Bisphenol A (BPA), an endocrine-disrupting chemical with immunomodulatory properties, may influence immune regulation,…